ACADIA Pharmaceuticals, Inc. Announces Presentation of Data on Pimavanserin Co-Therapy at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders

SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that Murray Rosenthal, D.O., a Fellow of the American Psychiatric Association, will present data from ACADIA’s pimavanserin Phase II schizophrenia co-therapy trial at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders in Montreux, Switzerland on February 5, 2008. Dr. Rosenthal was one of the lead investigators in ACADIA’s Phase II co-therapy clinical trial with pimavanserin and has extensive experience conducting clinical studies for patients with schizophrenia.